An approach where treatment is adjusted until measured goals are met, such as normal calprotectin or a healed gut lining, rather than only until symptoms improve.
Also called: t2t, treat-to-target, stride, stride-ii, tight control, target based treatment, stride ii, stride 2, treatment targets
It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.
Symptoms do not always match what is happening inside. Crohn's & Colitis UK says calprotectin can be raised even without symptoms, and tests check for anaemia and medicine side effects. Some teams use a 'treat to target' approach, aiming for healing of the gut lining and normal markers rather than just fewer symptoms. Monitoring may include blood and poo tests, scans, colonoscopy and, in some hospitals, home calprotectin kits.
Which biologics and targeted medicines are approved for Crohn's on the NHS?
NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.
It is a test on a small sample of poo that measures calprotectin, a protein released by white blood cells when the gut is inflamed. NICE recommends it to help doctors tell IBD apart from IBS. A high result suggests inflammation that needs looking into, but infections and some other conditions can raise it too. It is also used to monitor Crohn's once diagnosed.
Journal of Crohn's and Colitis via PubMed CentralSystematic reviewFeb 2020For professionals
Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Northern Lincolnshire and Goole NHS Foundation TrustLeafletDec 2025For patients
A hospital leaflet explaining the calprotectin poo test, which shows whether there is inflammation in the gut and is used both to help diagnose and to monitor conditions such as IBD. It explains how to collect the sample and warns that anti-inflammatory painkillers such as ibuprofen can affect the result, so ask your doctor before stopping or continuing them.
NICE guidance recommending the faecal calprotectin poo test to help tell inflammatory bowel disease apart from non-inflammatory conditions such as IBS.
NICE's recommendation that a faecal calprotectin poo test can be used to help doctors tell IBD apart from IBS. For adults with recent lower gut symptoms it applies when cancer is not suspected and proper quality checks and local pathways are in place; it is also recommended for children with suspected IBD who have been referred to a specialist. This guidance was first published as DG11 and NICE has since renumbered it HTG320 without changing it.
BMJ Open via PubMed CentralSystematic review2019For professionals
A UK review pooling studies of how accurate the calprotectin poo test is at detecting IBD in adults with long-standing gut symptoms. Only a handful of the eligible studies were done in general practice, and the results varied too much between studies to compare GP and hospital settings properly. It is useful background on why calprotectin helps but is not a perfect test.